title: Comparison of Fluvoxamine alone, Fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan--implications for management by family doctors.
abstract: This paper reports the result of a brief therapy attempt at treating panic in a busy outpatient psychiatric clinic. The patients were cases of panic referred from the various outpatient clinics within the hospital complex. The patients were divided into three groups at random using one of three modalities of treatment, i.e. cognitive behaviour therapy (CBT), CBT and Fluvoxamine (FVX), and FVX alone. The therapy was aimed for a maximum of nine sessions after which the patients were to be discharged. There were 14 patients in each group. The results show that all the groups were similar in the severity and scores pre treatment but after the different types of treatment there was a significant difference among them. The FVX alone group, showed significant improvement from the pretreatment levels but did not show as much improvement as the other groups and the mean score was only 9.07 after nine sessions. The best group was the CBT in combination with FVX. This indicates that the best way to treat panic is to combine drug treatment and psychological treatment. It is also shown from the study that the combination group requires less FVX than the FVX alone group. This finding has implications for the treatment of panic at the family physician clinic.
authors.affiliation: Psychotherapy Clinic, Hospital Universiti Sains Malaysia, Kubang Kerian, 16150 Kota Bahru, Kelantan.
authors.forename: M Z
authors.initials: MZ
authors.lastname: Azhar
mesh_terms: D000328:Adult; D015928:Cognitive Behavioral Therapy; D005194:Family Practice; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D008296:Malaysia; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000628:therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors